Author pages are created from data sourced from our academic publisher partnerships and public sources.
Pegaptanib for neovascular age-related macular degeneration.
- E. Gragoudas, A. Adamis, E. Cunningham, M. Feinsod, D. Guyer
- The New England journal of medicine
- 30 December 2004
BACKGROUND Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration. METHODS We conducted two concurrent,… Expand
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.
Age-related macular degeneration is the principal cause of registered legal blindness among those aged over 65 in the United States, western Europe, Australia, and Japan. Despite intensive research,… Expand
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
- E. Ng, D. Shima, P. Calias, E. Cunningham, D. Guyer, A. Adamis
- Nature Reviews Drug Discovery
- 1 February 2006
Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed against… Expand
A central role for inflammation in the pathogenesis of diabetic retinopathy
- A. Joussen, V. Poulaki, +9 authors A. Adamis
- Biology, Medicine
- FASEB journal : official publication of the…
- 1 September 2004
Diabetic retinopathy is a leading cause of adult vision loss and blindness. Much of the retinal damage that characterizes the disease results from retinal vascular leakage and nonperfusion. Diabetic… Expand
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
The vitreous levels of the angiogenic polypeptide vascular endothelial growth factor (also known as vascular permeability factor) were measured and compared in eyes with and without proliferative… Expand
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
PURPOSE Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO). DESIGN Prospective,… Expand
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
PURPOSE To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330), trials of ranibizumab in diabetic macular edema (DME). DESIGN Phase III, randomized, multicenter, double-masked,… Expand
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
OBJECTIVE To evaluate the safety and efficacy of intravitreal injections of an antigen-binding fragment of a recombinant humanized monoclonal antibody directed toward vascular endothelial growth… Expand
VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leukocyte-mediated endothelial cell injury and death in the diabetic retina.
- A. Joussen, T. Murata, A. Tsujikawa, B. Kirchhof, S. Bursell, A. Adamis
- The American journal of pathology
Endothelial cell death is a hallmark of diabetic retinopathy. Its occurrence is required for the formation of acellular (devitalized) capillaries, lesions that produce irreversible retinal ischemia… Expand